

Yolanda Aladro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2135850/publications.pdf>

Version: 2024-02-01

37
papers

643
citations

623734

14
h-index

610901

24
g-index

49
all docs

49
docs citations

49
times ranked

1076
citing authors

#	ARTICLE	IF	CITATIONS
1	Early predictive risk factors for dimethyl fumarate-associated lymphopenia in patients with multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 59, 103669.	2.0	4
2	Patients' self-assessment of essential tremor severity by a validated scale: A useful tool in telemedicine?. <i>Parkinsonism and Related Disorders</i> , 2022, 96, 22-28.	2.2	1
3	Baseline Inflammatory Status Reveals Dichotomic Immune Mechanisms Involved In Primary-Progressive Multiple Sclerosis Pathology. <i>Frontiers in Immunology</i> , 2022, 13, 842354.	4.8	1
4	Ultrasonographic and hemodynamic characteristics of patients with symptomatic carotid near-occlusion: results from a multicenter registry study. <i>Neuroradiology</i> , 2021, 63, 705-711.	2.2	7
5	Cancer diagnosis in a Spanish cohort of multiple sclerosis patients under dimethylfumarate treatment. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102747.	2.0	4
6	Predicting conversion to multiple sclerosis by assessing cognitive impairment in radiologically isolated syndrome. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 49, 102749.	2.0	3
7	Identification of the Immunological Changes Appearing in the CSF During the Early Immunosenescence Process Occurring in Multiple Sclerosis. <i>Frontiers in Immunology</i> , 2021, 12, 685139.	4.8	13
8	Risk and outcomes of COVID-19 in patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 3712-3721.	3.3	26
9	Effect of Ocrelizumab in Blood Leukocytes of Patients With Primary Progressive MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2021, 8, .	6.0	38
10	Genetic variation in NDFIP1 modifies the metabolic patterns in immune cells of multiple sclerosis patients. <i>Scientific Reports</i> , 2021, 11, 21371.	3.3	3
11	Comment on the article "Symptomatic carotid near-occlusion causes a high risk of recurrent ipsilateral ischemic stroke" by Gu et al.. <i>Journal of Neurology</i> , 2020, 267, 849-851.	3.6	1
12	New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab. <i>Frontiers in Neurology</i> , 2020, 11, 579438.	2.4	9
13	Three-Year Effectiveness of Dimethyl Fumarate in Multiple Sclerosis: A Prospective Multicenter Real-World Study. <i>CNS Drugs</i> , 2020, 34, 1275-1286.	5.9	6
14	Tolerability and safety of dimethyl fumarate in relapsing multiple sclerosis: a prospective observational multicenter study in a real-life Spanish population. <i>Journal of Neurology</i> , 2020, 267, 2362-2371.	3.6	21
15	Progression of carotid near-occlusion to complete occlusion: related factors and clinical implications. <i>Journal of NeuroInterventional Surgery</i> , 2020, 12, neurintsurg-2019-015638.	3.3	1
16	Activity-aware essential tremor evaluation using deep learning method based on acceleration data. <i>Parkinsonism and Related Disorders</i> , 2019, 58, 17-22.	2.2	23
17	Classification of radiologically isolated syndrome and clinically isolated syndrome with machine-learning techniques. <i>European Journal of Neurology</i> , 2019, 26, 1000-1005.	3.3	14
18	The risk of recurrent stroke at 24 months in patients with symptomatic carotid near-occlusion: results from CAOS, a multicentre registry study. <i>European Journal of Neurology</i> , 2019, 26, 1391-1398.	3.3	5

#	ARTICLE	IF	CITATIONS
19	Assessing fatigue in multiple sclerosis: Psychometric properties of the five-item Modified Fatigue Impact Scale (MFIS-5). <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731988798.	1.0	11
20	Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS. <i>Multiple Sclerosis Journal</i> , 2019, 25, 591-600.	3.0	13
21	Relationship between episodic memory and volume of the brain regions of two functional cortical memory systems in multiple sclerosis. <i>Journal of Neurology</i> , 2018, 265, 2182-2189.	3.6	5
22	Study of the possible link of 25-hydroxyvitamin D with Epstein-Barr virus and human herpesvirus 6 in patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2018, 25, 1446-1453.	3.3	16
23	Early risk of recurrent stroke in patients with symptomatic carotid near-occlusion: Results from CAOS, a multicenter registry study. <i>International Journal of Stroke</i> , 2017, 12, 713-719.	5.9	17
24	Continuous Monitoring of Essential Tremor Using a Portable System Based on Smartwatch. <i>Frontiers in Neurology</i> , 2017, 8, 96.	2.4	34
25	Face-to-Face or Telematic Cognitive Stimulation in Patients with Multiple Sclerosis and Cognitive Impairment: Why Not Both?. <i>Behavioural Neurology</i> , 2017, 2017, 1-6.	2.1	2
26	Neuromyelitis optica spectrum disorders. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e225.	6.0	134
27	Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort. <i>Journal of the Neurological Sciences</i> , 2016, 365, 16-21.	0.6	17
28	Gray Matter Involvement in Radiologically Isolated Syndrome. <i>Medicine (United States)</i> , 2016, 95, e3208.	1.0	22
29	Normal-appearing brain tissue analysis in radiologically isolated syndrome using 3 T MRI. <i>Medicine (United States)</i> , 2016, 95, e4101.	1.0	11
30	A comparison study of cognitive deficits in radiologically and clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , 2016, 22, 250-253.	3.0	39
31	Psychiatric disturbances in radiologically isolated syndrome. <i>Journal of Psychiatric Research</i> , 2015, 68, 309-315.	3.1	19
32	Neuropsychological syndromes in multiple sclerosis. <i>Psicothema</i> , 2013, 25, 452-60.	0.9	10
33	Thyrotoxicosis and cerebral venous sinus thrombosis, causality or chance alone?. <i>Endocrinología y Nutrición (English Edition)</i> , 2012, 59, 462-463.	0.5	3
34	On the Diagnosis of CADASIL. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 787-794.	2.6	14
35	Cytokine IL-1 beta but not IL-1 alpha promoter polymorphism is associated with Alzheimer disease in a population from the Canary Islands, Spain. <i>European Journal of Neurology</i> , 2008, 15, 1080-1084.	3.3	42
36	Butyrylcholinesterase, ApoE and Alzheimer's disease in a population from the Canary Islands (Spain). <i>Neuroscience Letters</i> , 2007, 427, 34-38.	2.1	7

#	ARTICLE	IF	CITATIONS
37	Prevalence and Incidence of Multiple Sclerosis in Las Palmas, Canary Islands, Spain. Neuroepidemiology, 2005, 24, 70-75.	2.3	39